npj Mental Health Research
January 31, 2026
Clayton Olash, Derrick Matthew Buchanan, Randi Brown et al.
1 citation
Magnesium-ibogaine, a formulation combining ibogaine with pre- and post-treatment magnesium, was recently found to yield rapid clinical improvements in U.S. Special Operations veterans with TBI and PTSD. Yet, its therapeutic phenomenology during such healing is unknown. We analyzed post-session narratives from 30 male veterans who, after a single open-label magnesium-ibogaine treatment,...
Addiction (Abingdon, England)
January 20, 2026
Tibor Markus Brunt
2 citations
Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive potential. Evidence from observational, open-label, and limited randomized placebo-controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in opioid and cocaine-dependent individuals, primarily...
Journal of Addiction Medicine
January 15, 2026
Dale Terasaki, Nathan Sackett, Andrew A. Monte
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD)....
Journal of Psychedelic Studies
January 6, 2026
Tobias Erny, Elba Yatziri Cano Montenegro, Joern Barth et al.
Abstract Background and Aims Parkinson's disease (PD) significantly impairs quality of life, and current treatments do not halt dopaminergic neurodegeneration. Evidence suggests that ibogaine, a naturally occurring indole alkaloid, may stimulate glial cell line-derived neurotrophic factor (GDNF) expression and affect dopamine transporter (DAT) function. This case study reports the effects of...